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Objectives: We built and validated a new heart failure (HF) prognostic model which integrates cardiopulmo-
nary exercise test (CPET) parameters with easy-to-obtain clinical, laboratory, and echocardiographic vari-
ables.
Background: HF prognostication is a challenging medical judgment, constrained by a magnitude of uncertainty.
Methods: Our risk model was derived from a cohort of 2716 systolic HF patients followed in 13 Italian centers.
Median follow up was 1041 days (range 4–5185). Cox proportional hazard regression analysis with stepwise
selection of variables was used, followed by cross-validation procedure. The study end-point was a composite
of cardiovascular death and urgent heart transplant.
Results: Six variables (hemoglobin, Na+, kidney function by means of MDRD, left ventricle ejection fractionrt Failure Model; CPET, Cardiopulmonary exercise test; HFSS, HF survival score; LVEF, Left Ventricular Ejection Fraction;
Left Ventricular End-Diastolic Volume; BMI, Body mass index; NYHA, New York Heart Association; PM, Pace maker;
resynchronization therapy; Hb, Hemoglobin; MDRD, Modiﬁcation of Diet in Renal Disease; BNP, Brain Natriuretic Peptide;
, Respiratory Rate; VE, Ventilation; RER, Respiratory exchange ratio; AT, Anaerobic threshold; VCO2, Carbon dioxide consump-
ino, IRCCS, Via Parea 4, 20138 Milan, Italy. Tel.: +39 02 58002586; fax: +39 02 58002283.
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2711P. Agostoni et al. / International Journal of Cardiology 167 (2013) 2710–2718[echocardiography], peak oxygen consumption [% pred] and VE/VCO2 slope) out of the several evaluated
resulted independently related to prognosis. A score was built from Metabolic Exercise Cardiac Kidney Indexes,
the MECKI score, which identiﬁed the risk of study end-point with AUC values of 0.804 (0.754–0.852) at 1 year,
0.789 (0.750–0.828) at 2 years, 0.762 (0.726–0.799) at 3 years and 0.760 (0.724–0.796) at 4 years.
Conclusions: This is the ﬁrst large-scale multicenter study where a prognostic score, the MECKI score, has been
built for systolic HF patients considering CPET data combined with clinical, laboratory and echocardiographic
measurements. In the present population, the MECKI score has been successfully validated, performing very
high AUC.© 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
The time course of heart failure (HF) is often insidious, and it is
inﬂuenced by several factors, including functional, neurohumoral
and compensatory mechanisms, concomitant diseases as well as psy-
chological well-being, environmental and genetic factors with vari-
able expression and penetrance. Therefore, prognostication is a
challenging medical judgment, constrained by a magnitude of uncer-
tainty. Cardiopulmonary exercise test (CPET) is a well recognized,
valuable and accurate tool for risk stratiﬁcation in HF. Among several
CPET-derived variables, peak VO2 [1,2], VE/VCO2 relationship [1,3–5],
and their combination [6,7] have been identiﬁed as predictors of
HF prognosis, and they are used for timing of heart transplant
[2,8,9]. Although the wealth of information derived from CPET for
HF prognosis has been informative and exciting, risk stratiﬁcation
with CPET-derived parameters need to be integrated into clinical
practice, and combining them with demographic data, medical his-
tory, laboratory values and HF treatment background might be help-
ful. This aspect has been scantily investigated and analyzed. Indeed,
at present, only HF survival score (HFSS) [10] and HF-Action Pre-
dictive Risk Score Model [11] include peak VO2 (the former) and ex-
ercise duration at CPET (the latter), among other clinical parameters
[10,12–14]. However, neither HF-Action Predictive Risk Score Model
nor HFSS include ventilatory parameters [3,4] and hemoglobin
[15,16], both holding a prognostic value in HF.
Hence, the purpose of the present work was to build a new risk
score for systolic HF, integrating measures with potential prognostic
value from CPET with established clinical, laboratory and echocardio-
graphic risk factors, in a sizeable multicenter cohort, recruited and
followed by experienced HF units in order to identify patients at
risk of cardiovascular death and urgent heart transplant. To do so,
we used a robust database derived from leading heart failure clinics
in Italy.
2. Methods
2.1. Population
Study cohort consisted of 2716 consecutive systolic HF patients, recruited and pro-
spectively followed in 13 Italian HF centers (see Appendix 2). The ﬁrst patient was rec-
ruited in February 1993 and the last one in September 2009. At enrollment, patients
were evaluated, and clinical history, physical, laboratory, ECG, echocardiographic,
and CPET data were collected. Inclusion criteria were: previous or present HF symp-
toms (NYHA functional classes I–III, stage C of ACC/AHA classiﬁcation) and former doc-
umentation of left ventricular systolic dysfunction (left ventricular ejection fraction,
LVEFb40%), stable clinical conditions with unchanged medications for at least three
months, ability to perform a CPET, no major cardiovascular treatment or intervention
scheduled. Furthermore, only subjects who performed what they considered a maximal
effort, regardless of the respiratory quotient reached, were included in the present analy-
sis. Other exclusion criteria were: history of pulmonary embolism, moderate-to-severe
aortic and mitral stenosis, pericardial disease, severe obstructive lung disease,
exercise-induced angina and signiﬁcant ECG alterations [17] or presence of any clinical
co-morbidity interfering with exercise performance.
2.2. Clinical, laboratory and echocardiographic evaluations
We recorded NYHA class, patients' weight and height. HF etiology was deﬁned as:
dilative ischemic and non ischemic cardiomyopathy (on the basis of either presence or
absence of relevant stenosis at coronary imaging, respectively), or cardiomyopathysecondary to valvular disease, and to other causes. Hemoglobin, serum sodium
(Na+), potassium (K+), and creatinine were measured. We calculated glomerular ﬁl-
tration rate as MDRD by using the following formula: 186.3*(crea)
−1.154
*(Age)
−
0.203
*0.75 for women [18]. We recorded left ventricle end-systolic (LVeSV) and
end-diastolic volumes (LVeDV) and LVEF (Simpson rule) on echocardiography [19].
2.3. Cardiopulmonary exercise test
All CPETs were performed using either an electronically braked cycle-ergometer
(2423 patients) or a treadmill (293 patients); for a proper comparison, VO2 data mea-
sured on treadmill were reduced by 10% [20], A ramp protocol and a modiﬁed Bruce
protocol was applied in CPET with cycle-ergometer and treadmill, respectively. The ex-
ercise protocol was set to achieve peak exercise in ~10 min [21]. In the absence of clin-
ical events, CPET was interrupted when patients stated that they had reached maximal
effort. We performed breath-by-breath analysis of expiratory gases and ventilation.
Anaerobic threshold was measured by V-slope analysis of VO2 and VCO2, and it was
conﬁrmed by ventilatory equivalents and end-tidal pressures of CO2 and O2. If no
agreement was obtained, AT was considered as not identiﬁed. Exercise-induced peri-
odic breathing was deﬁned as a cyclic ﬂuctuation of ventilation [22]. VO2/work rate re-
lationship was measured throughout the entire exercise (cycle-ergometer). VE/VCO2
slope was calculated as the slope of the linear relationship between VE and VCO2
from 1 min after the beginning of the loaded exercise and the end of the isocapnic buff-
ering period. Peak exercise oxygen pulse was calculated as peak VO2/peak heart rate
(HR). Predicted values of VO2 and HR were calculated as: peak VO2 pred=(Height−
Age)*20 if male, = (Height−Age)*14 if female; peak HR pred=(220−Age), if
male, = (210−Age) if female [20].
2.4. Patients' follow-up and prognosis
Patient's follow-up was carried out according to the local HF program in a theoret-
ically endless fashion. Follow-up ended with the last clinical evaluation in the center
where the patient had been enrolled, or with the patient's death (441 cardiovascular
death and 68 non cardiovascular death) or urgent cardiac transplantation (n=88).
The study end-point was the composite of cardiovascular death or urgent heart trans-
plant, including in the former stroke. Events were recorded at the follow-up visit. If a
patient did not show up at the scheduled follow-up visit, he or his family was con-
tacted by phone call, and the visit was rescheduled according to the patient's desire.
If a patient died outside the hospital where he was on follow-up, care was taken to ob-
tain medical records of the event and a report of the cause of death. Patients who died
of non-cardiovascular related causes were considered as censored at the time of the
event.
2.5. Data management
Since several possible sources of error in data recording and transfer might occur
throughout a multicenter research study, a data quality control was set up. Centro Car-
diologico Monzino (P. A. and G.C.) was the data director center, responsible for data
collection, while individual investigators were responsible for their own records.
Trained investigators were selected within the participating centers. A computerized
collection data form was created and approved, and clear rules for ﬁll in were
established. Regular feedback to investigators was organized by the data director cen-
ter: in addition, two “external” experts (M.P. and D.M.), not involved in patients' re-
cruitment, reviewed all the patients' data. Checking data quality included range and
consistency checks and checking for missing data. Developing boundaries for
out-of-range values required a collaborative effort between the data manager and
the investigators, and highest-priority missing data were discussed. Medical personnel
who collected the patients' data and deﬁned the cause of death were blinded to the
variables used in the MECKI score. All computerized data were stored on a secure net-
work that limited access to authorized individuals.
3. Statistical analysis
Categorical variables were presented, such as frequency and per-
centage, and they were compared by chi-square test. Numerical vari-
ables were summarized as means±SD, or medians and interquartile
Table 1
Patient demographic, laboratory, echocardiographic, CPET data and univariate analysis
of the analyzed parameters vs. the study end point (cardiovascular death+heart
transplant).
Mean±SD
median (75–25
interquartile)
N (%) HR Lower
CI
Upper
CI
ProbChiSq
Age (years) 60.3 ±12.4 2716 1.267 1.142 1.405 b.0001
Males/
females
2286
(84%)/
430
(16%)
1.108 1.006 1.219 0.0367
Height (cm) 170 ±8 2708 1 0.915 1.093 1
BMI (kg/m2) 26.5 ±4.3 2707 0.815 0.742 0.895 b.0001
NYHA class 2.2 ±0.6 2716 2.257 1.951 2.61 b.0001
HF ethiology 0.07
Idiopathic 1273 1
Ischemic 1240 1.234 1.017 1.496 0.03
Valvular 72 0.911 0.510 1.625 0.75
Other 130 1.160 0.760 1.771 0.49
PM 498
(18%)
1.954 1.558 2.45 b.0001
ICD 461
(17%)
1.504 1.184 1.909 0.0008
CRT 208
(8%)
2.329 1.692 3.206 b.0001
Hb (g/dL) 13.5 ±1.6 2271 0.722 0.652 0.8 b.0001
Na+ (mmol/
L)
139 ±3 2524 0.775 0.712 0.844 b.0001
K+
(mmol/L)
4.3 ±0.5 2517 0.93 0.846 1.023 0.1368
Crea
(mg/dL)
1.21 ±0.40 2532 1.343 1.248 1.446 b.0001
MDRD (mL/
min)
69.5 ±22.0 2531 0.698 0.631 0.772 b.0001
LVEF (%) 30.8 ±9.1 2716 0.539 0.486 0.597 b.0001
LVeSV (mL) 111 (153–80) 2203 1.423 1.303 1.554 b.0001
LVeDV (mL) 163 (211–121) 2203 1.435 1.326 1.552 b.0001
Ramp
protocol
(Watt/
min)a
10.4 ±2.3 2250
Peak VO2 (L/
min)
1.102 ±0.396 2699 0.538 0.483 0.599 b.0001
Peak VO2/kg
(mL/kg/
min)
14.4 ±4.4 2696 0.535 0.481 0.596 b.0001
Peak VO2 (%
of pred)
52.9 ±15.8 2695 0.52 0.47 0.576 b.0001
Peak HR
(bpm)
124 ±25 2689 0.792 0.72 0.87 b.0001
Peak HR (%
of pred)
79 ±16 2689 0.845 0.768 0.93 0.0006
Peak work
rate
(Watt)
81.1 ±33.3 2408 0.527 0.459 0.605 b.0001
Peak
O2pulse
(mL/bpm)
9.0 ±3.1 2672 0.616 0.555 0.684 b.0001
Peak TV (L) 1.5 ±0.5 2516 0.759 0.688 0.839 b.0001
Peak RR
(bpm)
32.0 ±6.9 2441 1.16 1.056 1.275 0.002
Peak VE (L/
min)
45.4 ±13.6 2640 0.845 0.769 0.93 0.0005
Peak RER 1.12 ±0.12 2552 1.026 0.927 1.137 0.6154
VO2 at AT
(mL/kg/
min)
10.1 ±3.2 2274 0.581 0.47 0.718 b.0001
VO2 at AT (%
of peak)
69 ±14 2274 1.162 1.043 1.296 0.0066
HR at AT
(bpm)
99.2 ±20 2198 0.864 0.774 0.964 0.0092
Work rate at
AT (Watt)
50.8 ±23.8 2139 0.69 0.603 0.79 b.0001
O2 pulse at
AT
(mL/bpm)
8.0 ±2.7 2199 0.67 0.595 0.754 b.0001
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LVeDV and LVeDS. Unpaired t-test or non parametric Mann–Whitney
test were used when appropriate for between-group comparison. A
pb0.05 was used to deﬁne statistical signiﬁcance.
Predictors for the study end-point were identiﬁed by ﬁtting a
Cox proportional hazard regression model with stepwise selection
of variables measured at starting date. In order to account for the
potential heterogeneity among clinical sites, the analysis was stra-
tiﬁed by recruiting center. Data from centers with b200 (n=6)
recruited patients were grouped. The initial set of predictors under-
going selection is reported in Table 1. In order to avoid a spurious se-
lection of predictors, due to the fact that the model was built and
tested on the same sample, albeit obtained from several centers, a
cross-validation procedure was employed: for 200 times, the sample
was randomly split in half, and the model including the independent
predictors was selected in the ﬁrst half (training set) and subsequent-
ly tested on the second half (testing set). For each variable, we com-
puted the number of times it was selected in the ﬁrst step, and the
number of times it was conﬁrmed (deemed as signiﬁcant) in the sec-
ond step. Among the considered covariates (Table 1), those that were
selected and conﬁrmed at least 70% of the times were considered as
independent outcome predictors. A risk score for two-year mortality
(or urgent transplant) was then devised as follows: all patients with
a censoring time shorter than 2 years were excluded, and all patients
with events occurring after 2 years were considered as censored. A
logistic regression model was employed, including all the previously
selected and validated independent predictors of outcomes. The
two-year risk score (predicted probability of event) was computed
for each subject by using the estimated logistic coefﬁcients. The
score was validated by dividing the sample in deciles of risk and by
comparing the observed events with the predicted events in each
decile (Hosmer–Lemeshow test). The capacity of the score to correct-
ly classify cases and controls was quantiﬁed by the area under the
ROC curve. Again, to avoid overestimates, the sample was randomly
split in two, the coefﬁcients were estimated in the ﬁrst half, and the
score was tested in the second half. Analogously, we computed ROC
curves for risk scores predicting events occurring within 1, 3, and
4 years. All analyses were performed using SAS statistical package
v.9.2 (SAS Institute Inc., Cary, NC).
4. Results
Patients' demographic, laboratory, echocardiographic and CPET
data are reported in Table 1, as well as the number of observations
available for each variable. HF treatment, at study run-in, included:
beta-blockers in 81% of patients, ACE-inhibitors in 79%, ARB- Blockers
in 14%, Diuretics in 80%, antialdosteonic drugs in 49%, anticoagulants
in 34%, digitalis in 33%, amiodarone in 26%, antiplatelet drugs in 44%.
Albeit the presence of a scheduled major cardiovascular treatment
was a study exclusion criterion, during the follow up 90 patients
underwent cardiac surgery, 53 hemodynamic procedure and 500
CRT/ICD implantation. Female gender was 16% of cases (430/2286).
Females had a higher LVEF 32.9±9.0% vs. 30.4±9.1% (pb0.0001).
Peak VO2 was higher in females compared to males if expressed as a %
of predicted value (59.0±16.7% of pred. vs. 51.7±15.3, pb0.0001)
and lower if expressed as mL/min/kg (12.9±4.0 mL/min/kg vs.
14.7±4.4, pb0.0001).
4.1. Prognosis
The median follow up was 1041 days (range 4–5185 days, 75–25
percentile: 1811–513), being the shorter follow up for an alive
patient 32 days. Cardiovascular death+urgent cardiac transplant
occurred in 529 cases (19%, 441 cardiac death and 88 urgent cardiac
transplant): 139, 110, 79, 51 events in the ﬁrst, second, third and
fourth year, respectively. In Table 1, univariate analysis of the analyzed
Table 2
Variables which remained signiﬁcantly related to the primary study endpoint (cardio-
vascular death+cardiac transplant) at multivariable Cox analysis with subsequent
cross validation.
Parameter Pr>ChiSq Hazard ratio 95% hazard
ratio
conﬁdence
limits
Selection Reconﬁrmation
Peak VO2
(% pred)
b.0001 0.708 0.614 0.816 84.0% 93.5%
VE/VCO2
slope
b.0001 1.291 1.165 1.431 85.0% 95.3%
Hb (g/dL) 0.0008 0.827 0.74 0.924 85.5% 94.2%
Na+
(mmol/L)
b.0001 0.796 0.719 0.881 96.5% 92.7%
LVEF (%) b.0001 0.699 0.61 0.802 90.0% 93.9%
MDRD
(mL/min)
b.0001 0.758 0.673 0.854 66.0% 81.1%
See Table 1 for abbreviations.
Fig. 1. Comparison between two-year predicted and observed risk of death in the en-
tire population, stratiﬁed by decile of risk. Relevant concordance was observed: p=
0.36 at Hosmer–Lemeshow Test. The straight line is an identity line.
Table 1 (continued)
Mean±SD
median (75–25
interquartile)
N (%) HR Lower
CI
Upper
CI
ProbChiSq
VE/VCO2
slope
33.0 ±7.7 2526 1.571 1.465 1.685 b.0001
VO2/work
slope
(mL/min/
Watt)a
9.4 ±2.0 1689 0.868 0.745 1.01 0.067
Atrial
ﬁbrillation
448
(17%)
1.395 1.118 1.741 0.0033
Periodic
breathing
540
(20%)
1.19 1.00 1.179 0.03
BMI = body mass index, NYHA = New York Heart Association, HF = heart failure, PM =
pace maker, ICD = implantable cardioverter–deﬁbrillator, CRT = cardiac resynchronization
therapy; Hb = hemoglobin, Na+= sodium, K+= potassium, Crea = creatinine, MDRD=
modiﬁcation of diet in renal disease, BNP=brain natriuretic peptide, LVEF= left ventricular
ejection fraction, LVeSV = left ventricular end-systolic volume, LVeDV = left ventricular
end-diastolic volume, VO2 = oxygen uptake, HR = heart rate, TV = tidal volume, RR =
respiratory rate, VE = ventilation, RER = respiratory exchange ratio, AT = anaerobic
threshold, VCO2 = carbon dioxide consumption. Italics: medians and interquartile range.
a Bike ergometer.
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analysis with subsequent cross validation, only hemoglobin, Na+,
MDRD, LVEF, peak VO2 (% predicted), and VE/VCO2 slope resulted in-
dependently related to prognosis (Table 2). On the basis of these 6
continuous variables, a score of Metabolic Exercise and Cardiac and
Kidney Indexes, the MECKI score, was deﬁned to identify the risk of
cardiovascular death+urgent heart transplant. A high concordance
was detected between two-year predicted and observed risk of
death in the entire population, stratiﬁed by decile of risk (Fig. 1).
Mean±SD of each variable included in the MECKI score for the
2-years mortality risk categories (b5%, 5–10%, 10–15%, >15%) is
reported in Table 3.
Fig. 2 reports the Kaplan–Meier survival curves stratiﬁed
according to risk class at 2 years, built on a subset of 2009 subjects
who had all the variables included in the MECKI score:b5% (906
cases), 5–10% (449 cases), 10–15% (236 cases), and >15% (418
cases). The ROC analysis of the MECKI score is reported in Fig. 3.
The MECKI score AUC was 0.804 (0.754–0.852) at 1 year (1758 survi-
vors and 83 events), 0.789 (0.750–0.828) at 2 years (1254 survivors
and 152 events), 0.762 (0.726–0.799) at 3 years (1114 survivors
and 205 events), and 0.760 (0.724–0.796) at 4 years (891 survivors
and 246 events).
A signiﬁcant worst prognosis was observed in patients with HF as-
sociated to coronary artery disease (Table 1), but etiology failed to
maintain an independent value at multivariate analysis. Finally, the
presence of the some drug categories was related to prognosis at uni-
variate analysis (Table 4), but at multivariable Cox analysis, only
beta-blockers (HR=0.692, 95% HR conﬁdence 0.542–0.883, p=
0.0031) and digitalis (HR=1.433, 95% HR conﬁdence 1.113–1.845,
p=0.0053) remained independently related to prognosis. However,
both beta-blockers and digitalis failed at cross-validation procedure.
If beta-blockers and digitalis were forced in the MECKI score, the
AUC curve at 2 years changed from 0.789 to 0.791.
A free web-based calculator was developed to allow an easy and
convenient calculation of the estimated risk of death. http://www.
cardiologicomonzino.it/Inglese/News/Pages/UserNewsHome.aspx
5. Discussion
Many HF risk stratiﬁcation tools were developed, each differing in
the type of sample from which it was derived and validated, the var-
iable used for risk stratiﬁcation, their utility in predicting mortality at
varying time points, and their ease of use. However, their application
in daily clinical practice is limited by their complexity [23], albeit afew easier to use approaches have been proposed [24] or because
they are considered as suboptimal in particular settings [23]. We de-
veloped a new predictive model built and validated on contemporary
HF population, based on simple parameters selected form several
measurements of clinical status, cardiac kidney function, anemia,
ﬂuid homeostasis and exercise performance. We aimed, to help clini-
cians in the risk stratiﬁcation of ambulatory HF patients.
Ultimately, several CPET and prognosis studies in systolic HF have
provided, improved, and updated risk stratiﬁcation. Since prediction
models should be designed to improve outcome deﬁnition in indi-
vidual patients, the integration of CPET risk factors with demogra-
phic data, medical history, laboratory values, and HF treatment
background is crucial. Unfortunately, the combination between intra-
and extra-CPET risk HF data has been poorly investigated. The MECKI
score ﬁlls the gap, and its clinical insight and originality lies in the abil-
ity to amalgamate a modern CPET risk interpretation with easily acces-
sible HF predictive data. Thus, the clinical difﬁculty of merging intra-
and extra-ergospirometry laboratory risk parameters is surmounted
Table 3
Mean±SD of the variables included in the MECKI score divided according to risk class at 2 years, b5%, 5–10%, 10–15%, and >15%.
LVEF
(%)
Peak VO2
(%)
Na+
(mmol/L)
Hb
(g/dL)
MDRD
(mL/min)
VE/VCO2 slope
b5% 36.74±7.35 61.92±14.16 140.4±3.1 13.9±1.5 77.09±20.91 28.67±4.6
5–10 29.28±7 51.55±11.29 139.7±3.2 13.4±1.6 68.89±20.26 32.62±5.13
10–15 26.88±7.08 45.6±10.25 138.8±3.2 13.3±1.5 62.94±20.77 34.86±5.45
>15% 23.75±6.77 38.2±9.94 137.7±3.7 13.0±1.64 56.43±20.21 41.98±7.96
See Table 1 for abbreviations.
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before the HF patient leaves the ergospirometry laboratory.
5.1. The MECKI score
The MECKI score is the result of a merging effort of 13 qualiﬁed HF
centers with signiﬁcant experience in CPET. Our study population
consists of systolic HF patients capable to perform a CPET, excluding,
therefore, subjects in NYHA class IV at enrollment as well as subjects
who failed to complete a maximal CPET. Out of the 6 indexes inde-
pendently related to prognosis at multivariable analysis, 2 are CPET-
derived parameters, either related to the cardiovascular (peak VO2)
or to the ventilatory (VE/VCO2 slope) response to effort. Beside these
parameters, the MECKI score uses an echocardiographic index of
cardiac systolic function (LVEF), 2 indexes of harmful comorbidities
(anemia and renal insufﬁciency: hemoglobin concentration and
MDRD, respectively), and one index of ﬂuid balance (serum Na+).
All the variables included within the MECKI score were continuous
values, so that the actual weight of each one was considered. TheFig. 2. Kaplan–Meier survival curves stratiﬁed according to risk class at 2 years. MECKI scor
curves were arbitrarily ended at 6 years.6 parameters had a signiﬁcant impact on the score calculation
(Table 2), their distribution signiﬁcantly overlapped (Table 3), con-
ﬁrming the need to pool the available information for an accurate
prognosis. Notably, all prognostic parameters were evaluated by
using a cross-validation procedure, splitting the population in two
halves and considering as signiﬁcant only parameters which were
selected and conﬁrmed in at least 70% of the 200 times they were
tested.
We analyzed 3 different units of VO2 at peak exercise, and specif-
ically peak VO2 as L/min, as mL/min/kg, and as % of predicted. The last
one was the only peak VO2 measurement included in the MECKI
score. Conversely, peak VO2% pred. has been preferred to peak VO2
absolute measurements in only a few reports [25–27]. The presence
of gender and age in peak VO2% pred. [20], as well as in the MDRD cal-
culation [18], is among the possible reasons why both disappear from
the ﬁnal score. In any case, if gender and age are forced in the MECKI
score, their additive value is negligible.
We calculated the VE/VCO2 slope up to the end of the isocapnic buff-
ering period. The average VE/VCO2 value observed in our populatione: b5% (906 cases), 5–10% (449 cases), 10–15% (236 cases), and >15% (418 cases). The
Fig. 3. ROC analysis of the MECKI score. The MECKI score AUC was 0.804 (0.754–0.852) at 1 year (1758 survivors and 83 events), 0.789 (0.750–0.828) at 2 years (1254 survivors and
152 events) 0.762 (0.726–0.799) at 3 years (1114 survivors and 205 events) and 0.760 (0.724–0.796) at 4 years (891 survivors and 246 events).
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ween poor and favorable prognosis in HF [3,4,28]. Our observa-
tions agree with several previous studies that have reported the
combined role of peak VO2 and VE/VCO2 in predicting HF prognosis
[6,7].
In the present population, periodic breathing was signiﬁcantly
related to prognosis as previously reported [5,22,29] at univariate
but not at multivariable analysis. However, albeit we used a simple
deﬁnition of periodic breathing, its assessment may be difﬁcult in
some cases. Moreover, it is possible, because of the multifactorial
genesis of periodic breathing, that the presence of other non
CPET-derived parameters in the MECKI score, such as LVEF, hemoglo-
bin, Na+ and MDRD, not previously evaluated, overcomes the role of
periodic breathing.
It is not surprising that LVEF remains signiﬁcantly related to prog-
nosis [10,23,30]. Indeed, several reports, some of which date back to
many years ago, suggested that LVEF, representing the extent of the
cardiac damage, has a prognostic value in HF, regardless of peak
VO2 [30].Table 4
Univariate analysis of the drug used at study run-in vs. the study end point (cardiovas-
cular death+heart transplant).
Parameter HR Lower CI Upper CI ProbChiSq
ACE-inhibitors 0.897 0.698 1.152 0.393
ARB-blockers 0.889 0.662 1.195 0.4363
Beta-blockers 0.572 0.466 0.701 b.0001
Diuretics 1.842 1.383 2.453 b.0001
Anti-aldosteronic drugs 1.207 1.01 1.444 0.039
Anti-platlets drugs 0.882 0.735 1.059 0.1789
Anticoagulants 1.423 1.189 1.702 0.0001
Digitalis 1.964 1.619 2.384 b.0001
Amiodarone 1.622 1.342 1.96 b.0001
ACE = angiotensin I converting enzyme, ARB = angiotensin II receptor.Low hemoglobin was associated with an increased risk of death in
our population, conﬁrming the report of anemia as a risk factor in HF
[15,16]. Hemoglobin effect on HF prognosis was not cancelled by VO2,
even if hemoglobin is a major determinant of peak VO2 [31].
Na+ and renal function are both well-known prognostic elements
for HF [18,32–34]. We showed that they maintain a prognostic role
even in the combined analysis of several variables. As expected,
MDRD was superior to serum creatinine level, since it also considers
gender and age [18].
The role of gender in HF prognosis is important, but deﬁnite data
are lacking [35,36]. In the present work, gender did not reach, at mul-
tivariable analysis, statistical signiﬁcance, but it is considered in other
parameters included in the MECKI score, such as peak VO2% pred. and
MDRD. We showed a better HF prognosis in women compared to
men. In the few previous reports available, women, albeit a lower
peak VO2, showed a better HF prognosis compared to men [37,38]. In-
terestingly, peak VO2 was previously reported as an absolute value
[37,38]. In the present report, peak VO2 as an absolute value is
lower in women compared to men, and higher if reported as % of
predicted.
Differently from previous reports [10,23,35,39], HF etiology was
not related to prognosis, albeit the presence of coronary artery dis-
ease was associated to a worse prognosis at univariable analysis. At
multivariable analysis, the presence of digitalis and beta-blockers at
study run-in was negatively and positively associated to prognosis,
respectively, while this is not the case for other drugs, such as
ACE-inhibitors, diuretics, ARB-blockers [10,23,40]. We believe that
this is related to the optimal treatment of the study population, and
the presence of digitalis and the absence of beta-blockers merely re-
ﬂect a more severe HF. Indeed, only a minority of patients, 19%,
were not on beta-blocker treatment at study run-in. These patients
had severe heart failure as demonstrated by peak VO2=13.9±4.2
and VE/VCO2 slope=34.7±8.9. Similarly, patients treated with digi-
talis, 33% of cases, had a higher incidence of atrial ﬁbrillation (25%)
and a peak VO2=14.1±4.2 and VE/VCO2 slope 33.4±7.8. Moreover,
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which might have inﬂuenced the MECKI score [40]. Indeed, it is pos-
sible that several patients of the present study were not in drug target
dose [41]. However, because the presence of beta-blockers and digi-
talis failed at cross-validation procedure, and because drug treatment
is a skewed decision and not an independent variable, we decided not
to add digitalis and beta-blockers into the MECKI score. We were
also supported in this approach by the ﬁnding that adding both
beta-blockers and digitalis to the MECKI score has a negligible effect
on the AUC.5.2. Comparison with other HF scores and clinical implications
Several HF scores have been suggested and investigated [10,11,23],
but their predictive accuracy is variable, depending on the illness
course, the background HF therapy, i.e. beta-blockers prescription [23],
device implantation [11,23], the type of events (i.e. inclusion of HF
hospitalization) and the duration of follow up. Hence, a comprehen-
sive comparative analysis between HF scores is difﬁcult and, sometimes,
not exhaustive [43].
HFSS was the ﬁrst multivariate HF model, and it was validated in
different settings [10,12–14,38,44,45]. Variables included are ische-
mic etiology, LVEF, mean blood pressure, heart rate, a QRS width of
120 milliseconds or more, serum sodium, and peak VO2. The model
divides patients into risk groups: low, moderate, and high. The
SHFM is the most validated model for HF prognostication [23], both
in clinical trials [46–48] and in community-based heart failure studies
[49]: even though effective and efﬁcient, the SHFM is complex, being
a 20-variable model, including age, sex, weight, LVEF, systolic blood
pressure, NYHA class, daily diuretic dose, sodium, hemoglobin, per-
cent lymphocytes, uric acid, and total cholesterol. In addition, ACE en-
zyme inhibitors, angiotensin receptor blockers, aldosterone blockers,
beta-blockers, statins, and devices are taken into account. Data aggre-
gation is demanding, but score deﬁnition is alleviated by online and
downloadable versions of calculators. The SHFM may be useful if
peak VO2 cannot be obtained, due to the inability to exercise, or if
peak VO2 is unreliable, due to low respiratory exchange ratio.
The HF-ACTION predictive risk score model is a new HF score [11]:
48 candidate variables were analyzed, including demographic data,
medical history, laboratory values, exercise parameters from maxi-
mal treadmill CPET, and measures of quality of life and depression.
Exercise duration on CPET, Kansas City Cardiomyopathy Question-
naire symptom stability score, higher serum urea nitrogen, and male
sex formed the best predictive model for the primary end-point
(all-cause mortality or hospitalization).
Each HF score has constructive and drawback features: the SHFM
is a complex 20-variable model and it uses NYHA class as a surrogate
for peak VO2, the HFSS is a 7-variable model that requires peak VO2,
often available only in specialized referral centers, and the HF-action
score promotes a 4-variables mode, in HF patients performing a maxi-
mal CPET, without including peak VO2.
Dowe need another HF score? TheMECKI score is a “CPET-centered”
score, and it emphasizes a modern interpretation of CPET results. For
the ﬁrst time, VE/VCO2 and % of predicted VO2 (rather than peak VO2)
were included in the model. It is worthy of note that these two CPET
variables were selected from 18 ergospirometric parameters, pro-
viding a desirable hierarchy, limiting the expanding number of CPET
risk parameters applied to predict outcome. In the MECKI score,
CPET scoring system was kept as simple as possible. In short, on one
hand the MECKI score underlines the central role of CPET for risk stra-
tiﬁcation, and on the other hand it underscores that both ventilatory-
and VO2-derived indexes should be considered. In addition, although
the MECKI score is “CPET-centered”, providing a modern and sophisti-
cated gas-exchange analysis, it underlines the opportunity to look “out-
side” the ergospirometry laboratory, and it corroborates that CPET riskutilization should be conducted in aggregation with non CPET outcome
data [10,11].
5.3. Study limitations
This study has a few limitations, which should be considered
when applying the MECKI score in the clinical setting. Firstly, we
studied a Caucasian population with ~50% of patients suffering from
idiopathic cardiomyopathy. Our population mainly consists in rela-
tively young HF males capable to perform an exercise and with a
low comorbidity rate. Therefore, the present population does not mir-
ror the real medical world. Consequently the MECKI score is only
applicable to HF subjects who have performed a maximal CPET. More-
over, we do not know if the MECKI score maintains its prognostic
power in other HF populations, such as subjects not on optimized
treatment, or in not Caucasian or elderly subjects. Regarding the HF
population studied, it is acknowledged that, albeit we selected our
HF population to avoid signiﬁcant comorbidities which could directly
affect exercise capacity and prognosis, we did not exclude from the
present study patients with systemic hypertension, diabetes, and
moderate COPD. Accordingly, we cannot rule out a speciﬁc role of
these comorbidities on exercise capacity, on prognosis, and conse-
quently on the MECKI score. The above-mentioned characteristics of
our study population and particularly the capability of performing a
CPET, make the comparison between our data and those of HF regis-
try or epidemiological studies [23,32,50–53] difﬁcult. Altogether the
above reported limitations explain why we obtained a relative small
number of patients per center. Secondly, we did not consider, on
top of the NYHA classiﬁcation, ﬁndings such as history of HF hospital-
ization, presence of mitral regurgitation, 3rd tone, right heart dys-
function, jugular distension, hepatomegaly, or peripheral edema, all
surrogates of clinical severity. Thirdly, we observed a RERb1.0 in
330 (12%) patients, which suggests a submaximal exercise test.
However, CPET was self-interrupted by the patients when they
had reached maximal effort. Notably, in 74 out of 330 patients,
exercise-induced periodic breathing was observed, questioning the
value of RER as a parameter of peak exercise achievement. Moreover,
it should be noted that the value of RER was not related to prognosis
even at univariate analysis. Fourthly, we only analyzed ECGs for the
presence of atrial ﬁbrillation or for exercise-induced ECG changes.
Therefore, the presence of intraventricular delay was not taken into
account, albeit left bundle branch block is a recognized HF prognostic
parameter. Neither BNP nor NT-pro BNP plasma level, obtained in 793
patients (29% of cases), were considered in the present analysis, be-
cause of jeopardized data, due to the different attitudes of the centers
on this regard (routine use in a minority, different peptide assess-
ment, different methods for the same peptide), not allowing pooling
and statistical analysis. Fifth, several formulas are available to esti-
mate renal function. We used the MDRD formula [18], but others
have been used including the Cockcroft–Gault [54]. We arbitrarily
chose MDRD because we are hoping for a widespread use of the
MECKI score and racial differences are taken into account in MDRD
but not in Cockcroft–Gault formula. Finally it should be acknowl-
edged that, because the follow-up was long, many patients under-
went to therapy upgrading , including ICD and CRT which may, per
se, have inﬂuenced the prognosis.
5.4. In conclusion
In this is study parameters obtained from CPET have been com-
bined to other prognostics variables derived from clinical, echocar-
diographic and laboratory settings in a large cohort of systolic HF
patients followed in experienced centers. This allows us to build up
a valuable long-term HF prognostic score. Indeed, the MECKI score
combines peak VO2% of predicted, VE/VCO2 slope, LVEF, hemoglobin,
Na+, and MDRD. Thus the MECKI score is built on only 4 easy to
2717P. Agostoni et al. / International Journal of Cardiology 167 (2013) 2710–2718obtain clinical variables on top of the two most known prognostic pa-
rameters obtained from CPET. Accordingly the MECKI score is a sim-
ple, reliable, easy to calculate, personalized heart failure prognostic
tool. At present, MECKI is the long term prognostic score for systolic
HF with the highest AUC [43]. However, the day-by-day use of the
MECKI score as well as the comparisons with existing standards is
the next steps needed.
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Appendix 1
Other members of the MECKI score research group are: Centro
Cardiologico Monzino, IRCCS, Milano: Laura Antonioli, Chiara
Segurini, Erica Bertella, Stefania Farina, Francesca Bovis, Cardiologia
Riabilitativa, Azienda Ospedali Riuniti, Ancona: Francesca Pietrucci,
Istituto Auxologico Italiano: Gabriella Malfatto, Cardiologia SUN,
Ospedale Monaldi Napoli, Teo Roselli, Andrea Buono, Raffaele Calabrò,
CNR-Milano: Renata De Maria, “S. Maugeri” Foundation, IRCCS,
Cassano Murge: Daniela Santoro, Saba Campanale, Domenica Caputo,
“S. Maugeri” Foundation, Tradate: Donatella Bertipaglia, Ospedali
Riuniti and University of Trieste: Emanuela Berton.
Appendix 2
Patients' recruitment: 602 patients were recruited and followed at
Centro Cardiologico Monzino, Milan, 334 at S. Maugeri Foundation,
Cassano Murge, 218 at Fondazione G. Monasterio, Pisa, 127 at S. Maugeri
Foundation, Tradate, 57 at Lancisi Hospital, Ancona, 134 at Monaldi
Hospital, Naples, 270 at S. Spirito Hospital, Rome, 22 at S. Luca Hospital,
Milan, 63 at S. Paolo Hospital, Milan, 266 at Ospedali Civili, Brescia, 201
at Ospedali Riuniti, Trieste, 357 at S. Maugeri Foundation, Veruno and
64 at S. Camillo Hospital, Rome.
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